David P. Jr. Wood

David P. Jr. Wood's AcademicInfluence.com Rankings

David P. Jr. Wood

Philosophy

#9775

World Rank

#13383

Historical Rank

Logic

#6730

World Rank

#8276

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David P. Jr. Wood's Degrees

Doctorate Medicine Harvard University

Why Is David P. Jr. Wood Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David P. Jr. Wood's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. (2003) (2206)
Quality of life and satisfaction with outcome among prostate-cancer survivors. (2008) (1335)
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. (2011) (600)
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. (2009) (430)
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. (2001) (425)
Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA (2011) (364)
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. (2002) (328)
Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer (1995) (295)
Prediction of erectile function following treatment for prostate cancer. (2011) (284)
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. (1998) (254)
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. (2001) (229)
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. (2011) (206)
Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer (1989) (204)
Renal mass core biopsy: accuracy and impact on clinical management. (2007) (191)
Effects of Lycopene Supplementation in Patients with Localized Prostate Cancer (2002) (182)
Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. (2006) (179)
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. (2015) (178)
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. (2009) (178)
Accuracy of percutaneous core biopsy in management of small renal masses. (2009) (176)
Measuring health‐related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI) (2007) (174)
Soy Isoflavones in the Treatment of Prostate Cancer (2003) (169)
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy (2009) (167)
Identification of bone marrow micrometastases in patients with prostate cancer (1994) (162)
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial (2018) (151)
Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. (2000) (145)
Delays in diagnosis and bladder cancer mortality (2010) (141)
Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. (2010) (126)
Management of primary urethral cancer. (1998) (122)
Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. (1998) (121)
Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. (2010) (119)
Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. (1997) (118)
Lymph node size does not correlate with the presence of prostate cancer metastasis. (1999) (116)
Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. (1989) (116)
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 (2011) (116)
Matched comparison of robotic-assisted and open radical cystectomy. (2012) (110)
Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. (1994) (110)
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. (2011) (108)
Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. (2000) (107)
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. (1992) (106)
Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. (2000) (106)
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. (2003) (106)
Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710) (2010) (105)
Outcome of palliative urinary diversion in the treatment of advanced malignancies (1999) (105)
Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. (2004) (100)
Prognostic implications of a positive apical margin in radical prostatectomy specimens. (1998) (94)
Racial treatment trends in localized/regional prostate carcinoma: 1992–1999 (2005) (94)
Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. (1998) (91)
Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. (1998) (91)
Detection of Aggressive Primary Prostate Cancer with 11C-Choline PET/CT Using Multimodality Fusion Techniques (2009) (90)
THERAPEUTIC IRRADIATION FOR PATIENTS WITH AN ELEVATED POST-PROSTATECTOMY PROSTATE SPECIFIC ANTIGEN LEVEL (1997) (88)
Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. (1998) (88)
Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. (2000) (86)
Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. (2002) (85)
Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. (2003) (84)
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. (2009) (84)
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers (1992) (82)
Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. (1993) (81)
Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study. (1989) (81)
Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. (2014) (79)
Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer (2012) (78)
Image-guided biopsy in the evaluation of renal mass lesions in contemporary urological practice: indications, adequacy, clinical impact, and limitations of the pathological diagnosis. (2005) (77)
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. (2012) (77)
Should African‐American men be tested for prostate carcinoma at an earlier age than white men? (1999) (76)
Incidence and significance of positive urine cultures in patients with an orthotopic neobladder. (2003) (76)
Should Gleason score 7 prostate cancer be considered a unique grade category? (1999) (75)
EGR-1 Induction Is Required for Maximal Radiosensitivity in A375-C6 Melanoma Cells* (1996) (74)
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). (2009) (74)
Patient preoperative expectations of urinary, bowel, hormonal and sexual functioning do not match actual outcomes 1 year after radical prostatectomy. (2011) (72)
Photoacoustic tomography: a potential new tool for prostate cancer (2010) (71)
Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. (1999) (70)
Hydro-jet assisted laparoscopic partial nephrectomy: initial experience in a porcine model. (2000) (69)
How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival? (2001) (69)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer (2010) (68)
Urothelial Tumors of the Bladder (2012) (66)
Intraoperative, perioperative, and long-term complications of radical prostatectomy. (2001) (66)
Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. (2002) (61)
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. (1995) (60)
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. (2008) (59)
Bladder cancer: narrowing the gap between evidence and practice. (2009) (58)
Radical cystectomy for carcinoma of the bladder in the elderly patient. (1987) (57)
Urinary diversion-related outcome in patients with pelvic recurrence after radical cystectomy for bladder cancer. (1999) (57)
Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. (1994) (57)
Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. (2013) (56)
Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder (1997) (55)
Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer. (2003) (54)
Retroperitoneal neural sheath tumors: Cleveland Clinic experience. (1989) (53)
Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques (2011) (52)
Risk factors and quality of life for post-prostatectomy vesicourethral anastomotic stenoses. (2012) (51)
Short-term health outcome differences between robotic and conventional radical prostatectomy. (2007) (50)
Stent-change therapy in advanced malignancies with ureteral obstruction. (2005) (49)
The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. (2004) (48)
Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. (1998) (48)
Identifying Susceptibility Genes for Prostate Cancer—A Family-Based Association Study of Polymorphisms in CYP17, CYP19, CYP11A1, and LH-β (2005) (47)
Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. (2007) (47)
Utility of extended pattern prostate biopsies for tumor localization (2008) (47)
Relationship of p21WAF1 expression with disease‐free survival and biochemical recurrence in prostate adenocarcinomas (PCa) (1999) (47)
Role of radical prostatectomy in patients with prostate cancer of high Gleason score (1999) (46)
Common Variation in the BRCA1 Gene and Prostate Cancer Risk (2007) (45)
Detection and comparison of specific hemin binding by Porphyromonas gingivalis and Prevotella intermedia (1997) (45)
Role of mitochondria in ciprofloxacin induced apoptosis in bladder cancer cells. (2002) (45)
Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. (1999) (44)
Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle‐invasive bladder cancer (2012) (44)
Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation. (1995) (43)
Incidence of benign and malignant prostate tissue in biopsies of the bladder neck after a radical prostatectomy. (1995) (43)
Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia (2006) (43)
DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. (1991) (42)
Urothelial carcinoma of the prostate. (2007) (42)
Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. (2003) (42)
Extraperitoneal v intraperitoneal robotic prostatectomy: analysis of operative outcomes. (2007) (42)
Does robotic technology mitigate the challenges of large prostate size? (2010) (41)
Hydro-jet dissection for laparoscopic nephrectomy: a new technique. (1999) (40)
Risk perception and concern among brothers of men with prostate carcinoma (2004) (39)
Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. (1996) (39)
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. (2011) (38)
Radical prostatectomy nomograms in black American men: accuracy and applicability. (2003) (38)
p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. (1999) (38)
Validation of automatic target volume definition as demonstrated for 11C-choline PET/CT of human prostate cancer using multi-modality fusion techniques. (2010) (37)
Understanding the role of percutaneous biopsy in the management of patients with a small renal mass. (2012) (37)
Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer. (1998) (37)
Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer (2001) (36)
Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness. (1999) (36)
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. (2008) (35)
The risk of radical cystectomy. (1989) (35)
Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer. (1992) (35)
Focal positive surgical margins decrease disease-free survival after radical prostatectomy even in organ-confined disease. (2008) (35)
Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer (1998) (34)
Prostate Cancer Diagnosis, Staging and Survival (2004) (34)
Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. (2002) (34)
Racial differences and prognostic significance of tumor location in radical prostatectomy specimens (1998) (33)
Orthotopic urinary diversion is a viable option in patients undergoing salvage cystoprostatectomy for recurrent prostate cancer after definitive radiation therapy. (1997) (33)
Re: extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the surveillance, epidemiology, and end results program. (2011) (33)
Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in CT2B prostate cancer -24 month results (1997) (32)
Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. (1999) (31)
Understanding criteria for surveillance of patients with a small renal mass. (2012) (31)
Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? (2009) (30)
Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial. (2015) (30)
A one-day couple group intervention to enhance sexual recovery for surgically treated men with prostate cancer and their partners: a pilot study. (2013) (30)
Robot-assisted salvage prostatectomy: evaluation of initial patient-reported outcomes. (2010) (30)
Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma (2000) (30)
Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. (2004) (29)
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. (2018) (29)
Role of lymphadenectomy in renal cell carcinoma. (1991) (29)
Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. (2007) (29)
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. (2007) (29)
Preparing Patients and Partners for Recovery From the Side Effects of Prostate Cancer Surgery: A Group Approach. (2016) (28)
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. (2013) (28)
Female pseudohermaphroditism due to congenital adrenal hyperplasia complicated by adenocarcinoma of the prostate and clear cell carcinoma of the endometrium. (1996) (27)
Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease‐free survival after radical prostatectomy (2001) (26)
Clinical interpretation of the Expanded Prostate Cancer Index Composite-Short Form sexual summary score. (2009) (25)
Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. (2000) (25)
Lycopene in the treatment of prostate cancer (2002) (25)
Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators. (1994) (24)
Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. (1997) (23)
Stratification of postprostatectomy urinary function using expanded prostate cancer index composite. (2013) (23)
The significance and management of transitional cell carcinoma of the prostate. (1990) (23)
Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12 (2006) (23)
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. (2001) (21)
Infusional interleukin‐2 and 5‐fluorouracil with subcutaneous interferon‐α for the treatment of patients with advanced renal cell carcinoma (2000) (21)
Expanded Prostate Cancer Index Composite versus Incontinence Symptom Index and Sexual Health Inventory for Men to measure functional outcomes after prostatectomy. (2009) (21)
Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: a comparison between African-American and white men. (2000) (20)
The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy. (1999) (20)
Early urinary retention after catheter removal following radical prostatectomy predicts for future symptomatic urethral stricture formation. (2007) (20)
Fertility issues for men with newly diagnosed prostate cancer. (2007) (20)
The use of mineral oil to manage the nondeflating Foley catheter. (1993) (19)
Metallothionein gene expression in bladder cancer exposed to cisplatin. (1993) (19)
Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. (2011) (18)
The role of magnetic resonance imaging in the staging of bladder carcinoma. (1988) (18)
Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? (2000) (17)
The Role of Percutaneous Renal Biopsy in the Management of Small Renal Masses (2011) (17)
[Primary small cell carcinoma of the bladder]. (1999) (17)
Optimizing outcomes at every stage of bladder cancer: do we practice it? (2009) (16)
Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Do Mixed Histological Features Affect Survival Benefit from Neoadjuvant Platinum-Based Combination Chemotherapy in Patients with Locally Advanced Bladder Cancer? A Secondary Analysis of Southwest Oncology Group-Directed Intergr (2011) (16)
Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. (2014) (16)
Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. (1998) (16)
Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial (2017) (16)
Is residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures? (2010) (16)
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia : SWOG S 9917 (2011) (15)
Presence of circulating prostate cancer cells in African American males adversely affects survival. (2002) (15)
Significance of the Gleason scoring system after neoadjuvant hormonal therapy. (2000) (15)
Converting from open to robotic prostatectomy: key concepts. (2010) (15)
Radiation therapy for a rising PSA level after radical prostatectomy. (1999) (15)
Retained straight catheter: complication of clean intermittent catheterization. (1986) (14)
Southwest Oncology Group studies in bladder cancer (2003) (14)
Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa. (1988) (14)
Margin control in robotic and laparoscopic prostatectomy: what are the REAL outcomes? (2010) (14)
Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. (2000) (14)
Treatment outcome after radical prostatectomy is not adversely affected by a pre-existing penile prosthesis. (1998) (13)
The impact of anterior urethropexy during robotic prostatectomy on urinary and sexual outcomes. (2011) (13)
1417 EFFICIENT DELIVERY OF RADICAL CYSTECTOMY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER: A MULTIDISCIPLINARY APPROACH (2011) (12)
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. (2001) (12)
Evolving role of renal biopsy in small renal masses. (2009) (11)
A Comparison of Extraperitoneal and Intraperitoneal Approaches for Robotic Prostatectomy (2012) (11)
Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer. (2001) (10)
Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. (2017) (9)
A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG) (2008) (9)
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. (2005) (9)
Re: Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. (2013) (9)
Genomic characterization of asymptomatic Escherichia coli isolated from the neobladder. (2011) (8)
Renal sarcomas of childhood. (1990) (8)
Clinical interpretation of the prostate biopsy. (2003) (7)
1234: Presence, Location and Significance of Prostate Cancer in Patients Undergoing Radical Cystoprostatectomy: Feasibility of Prostate Capsule Sparing Cystectomy (2006) (7)
Re: international phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. (2012) (7)
911: Lymphovascular Invasion is an Independent Predictor of Survival in CTl Bladder Cancer (2005) (6)
Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. (2009) (6)
Treatment of metastatic transitional cell carcinoma following renal transplantation. (1989) (6)
Early postoperative urinary and sexual function predicts functional recovery 1 year after prostatectomy. (2013) (6)
Re: current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). (2014) (6)
552: Patient-Reported Outcomes after Retropubic, Laparoscopic, or Robot-Assisted Prostatectomy: Results from a Prospective, Multi-Center Study (2007) (6)
Re: Randomized Noninferiority Trial of Reduced High-Dose Volume versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004) (2014) (6)
Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. (2007) (6)
Ras oncogene point mutations in bladder cancer resistant to cisplatin (2004) (5)
SIGNIFICANCE OF TERTIARY PATTERN 5 IN PROSTATE NEEDLE BIOPSIES WITH GLEASON SCORE OF 3+4 OR 4+3 PROSTATE CANCER: PATHOLOGIC CORRELATION FOLLOWING RADICAL PROSTATECTOMY (2009) (5)
Prostate Cancer Old Problems and New Approaches (1996) (5)
Review article Salvage surgery for locally recurrent prostate cancer after radiation therapy. (1998) (5)
Prostate cancer old problems and new approaches (1996) (5)
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). (1996) (5)
Identifying Better Practices for Early-stage Bladder Cancer (2011) (5)
1151: Perioperative Quality Care Indicators of Retropubic, Laparoscopic, and Robotic Prostatectomy: Results from a National, Multi-Center, Prospective Cohort (2006) (5)
36: Measuring Health-Related Quality of Outcomes in Bladder Cancer Patients using the Newly Validated Bladder Cancer Index (BCI) (2006) (4)
Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium (2021) (4)
Re: Cisplatin Sensitivity of Testis Tumour Cells is Due to Deficiency in Interstrand-Crosslink Repair and Low ERCC1-XPF Expression (2011) (4)
"Stand-up" urologic endoscopy. (1996) (4)
18: Measuring Quality-of-Life after Surgery: Development and Validation of the Convalescence and Recovery Evaluation (CARE) (2007) (4)
GENDER DIFFERENCES IN URINARY FUNCTION AFTER ORTHOTOPIC NEOBLADDER (1999) (4)
Re: metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. (2013) (4)
Methods of urinary diversion following radical cystectomy. (1994) (3)
Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. (2009) (3)
813: Oncology Rather than Laparoscopy Surgical Experience is More Important in Learning to Perform a Robot-Assisted Laparoscopic Radical Prostatectomy (2004) (3)
Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. (2014) (3)
[Main grade of Gleason's 7 score of the surgical sample correlated with biologic progression in patients treated for total prostatectomy]. (2002) (3)
[Comparison among patients considered candidates for radical prostatectomy in academic institutes in different countries]. (1998) (3)
Common Variation in the BRCA 1 Gene and Prostate Cancer Risk (2007) (3)
Understanding Early Functional Recovery After Robotic Prostatectomy (2012) (3)
Re: Expression Signature of E2F1 and its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors. (2011) (3)
35: Development and Validation of the Bladder Cancer Index (BCI): A Disease Specific Measure of Quality of life (2006) (3)
Re: Genome Sequencing Identifies a Basis for Everolimus Sensitivity (2013) (2)
Comment on: Response of hormone refractory prostate cancer to lycopene by de la Taille, A. et al. (2002) (2)
Ureter, Bladder, Penis, and Urethra (2006) (2)
Is it time to revise our evaluation of hematuria? (2009) (2)
Orthotopic urinary diversion in women. (2000) (2)
Re: Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis (2014) (2)
IMPACT OF PELVIC LYMPHADENECTOMY ON DISEASE- FREE SURVIVAL AFTER RADICAL PROSTATECTOMY: A MULTICENTER STUDY (2008) (2)
Re: Molecular Pathways of Urothelial Development and Bladder Tumorigenesis (2011) (2)
Re: interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. (2013) (2)
1708 DO MIXED HISTOLOGIC FEATURES AFFECT SURVIVAL BENEFIT FROM NEO-ADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER? (2010) (2)
Re: recurrence of high-risk bladder cancer: a population-based analysis. (2014) (2)
Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. (2012) (2)
Diagnostic Efficacy of [11C]Choline Positron Emission Tomography/Computed Tomography Compared with Conventional Computed Tomography in Lymph Node Staging of Patients with Bladder Cancer prior to Radical Cystectomy (2013) (2)
Re: survival after treatment for carcinoma invading bladder muscle: a dutch population-based study on the impact of hospital volume. (2013) (2)
1530 UNDERSTANDING REAL-WORLD CRITERIA FOR THE SURVEILLANCE OF PATIENTS WITH A SMALL RENAL MASS (2011) (2)
Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations. (1996) (2)
Accuracy of the Extent of Bladder Cancer Nodal Metastases Found at Pelvic Lymphadenectomy at the Time of Cystectomy: Relation to Primary Tumor Stage (2010) (2)
Office management of urinary stomas. (1988) (2)
Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. (2013) (1)
The molecular staging of prostate cancer. (1995) (1)
Re: Lymph Node Density for Patient Counselling about Prognosis and for Designing Clinical Trials of Adjuvant Therapies after Radical Cystectomy (2014) (1)
Re: Low Dose BCG Regimen in T1 Transitional Cell Carcinoma of the Bladder: Long Term Results (2011) (1)
Management of Urologic Malignancies (2004) (1)
Re: Pathological Response to Neoadjuvant Chemotherapy for Muscle-Invasive Micropapillary Bladder Cancer (2014) (1)
Re: Bladder Cancer: Evaluation of Staging Accuracy Using Dynamic MRI (2012) (1)
Re: surgery-related complications of robot-assisted radical cystectomy with intracorporeal urinary diversion. (2012) (1)
Surgical therapy for intermediate risk prostate cancer. (2011) (1)
PREDICTORS OF BIOCHEMICAL RECURRENCE IN PATHOLOGICALLY ORGAN-CONFINED PROSTATE CANCER: ANALYSIS OF PREOPERATIVE PSA, AGE, RACE, GLEASON SCORE, TUMOR VOLUME, DNA PLOIDY and PROLIFERATIVE ACTIVITY (1999) (1)
A PHASE III BLINDED STUDY OF IMMEDIATE POST‐TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON‐MUSCLE INVASIVE BLADDER CANCER: SWOG S0337: PNFLBA‐10 (2017) (1)
IMPACT OF POSITIVE SURGICAL MARGINS ON DISEASE FREE SURVIVAL BETWEEN AFRICAN AMERICAN AND CAUCASIAN MEN FOLLOWING RADICAL PROSTATECTOMY (1999) (1)
Re: diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. (2014) (1)
Re: Radiotherapy With or Without Chemotherapy in Muscle-Invasive Bladder Cancer (2012) (1)
Primary Carcinoma in situ of the Urinary Bladder: Diagnosis and Management (1999) (1)
Focal Positive Surgical Margins Decrease Disease-Free Survival Following Radical Prostatectomy Even in Organ-Confined Disease (2008) (1)
Re: Response of hormone refractory prostate cancer to lycopene. (2002) (1)
Bladder cancer: deciding on appropriate surgery. (1989) (1)
1122: Success of Radiofrequency Ablation (RFA) as Assessed by Radiographic and Histologic Criteria (2006) (1)
Re: Prospective Evaluation of MRI, 11C-Acetate PET/CT and Contrast-Enhanced CT for Staging of Bladder Cancer (2013) (1)
Re: loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. (2012) (1)
Re: Long-Term Results of Maintenance Treatment of Mitomycin C or Alternating Mitomycin C and Bacillus Calmette-Guérin Instillation Therapy of Patients with Carcinoma In Situ of the Bladder: A Subgroup Analysis of the Prospective Finnbladder 2 Study with a 17-Year Follow-up (2013) (1)
Comprar Bladder Cancer · Diagnosis, Therapeutics, and Management | Lee, Cheryl T. | 9781588299888 | Springer (2009) (1)
[Treatment of colo-vesical fistulas in one-stage operation]. (1998) (1)
Re: Gender-Dependent Cancer-Specific Survival Following Radical Cystectomy (2014) (1)
Re: Use of Potentially Curative Therapies for Muscle-Invasive Bladder Cancer in the United States: Results from the National Cancer Data Base (2014) (1)
Her-2 / neu Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder : Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors 1 (2001) (1)
Re: bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. (2012) (1)
POD-05.08: Predicting the Long-Term Risk of Prostate Cancer-Specific Mortality After Radical Prostatectomy (2009) (1)
Re: A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression (2011) (1)
470 DO MARGINS MATTER? THE INFLUENCE OF POSITIVE SURGICAL MARGINS ON PROSTATE CANCER-SPECIFIC MORTALITY (2011) (1)
Laparoscopy in urologic surgery: modern applications of the cystoscope. (1993) (1)
Re: A Phase II Trial of Neoadjuvant Erlotinib in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: Clinical and Pathological Results (2011) (1)
157: Geographic and Demographic Variations in the Use of Pelvic Lymph Node Dissection in Men Diagnosed with Clinically Localized Prostate Cancer (2004) (1)
PATIENT AND DISEASE CHARACTERISTICS ASSOCIATED WITH AN ADEQUATE LYMPH NODE DISSECTION DURING RADICAL CYSTECTOMY (2008) (0)
Re: two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of ta and t1 transitional cell bladder cancer: a prospective, randomized controlled study. (2011) (0)
Early Impressions of High-Intensity Focused Ultrasound for Prostate Cancer (2008) (0)
Re: VEGFR and EGFR Inhibition Increases Epithelial Cellular Characteristics and Chemotherapy Sensitivity in Mesenchymal Bladder Cancer Cells (2011) (0)
Evolving Therapies for Prostatic Carcinoma, Encompassing Orchiectomy, Estrogens, and Estramustine (1997) (0)
973 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE IS A THERAPEUTIC TARGET FOR BLADDER CANCER (2010) (0)
Parametric PET/MR fusion imaging in prostate cancer (2010) (0)
Editorial comment. (2010) (0)
Re: Should Intravesical Bacillus Calmette-Guérin be Employed in Transplant Recipients With Bladder Carcinoma? (2011) (0)
Convalescence And Recovery Evaluation (2016) (0)
Re: Standardized analysis of frequency and severity of complications after robot-assisted radical cystectomy. (2013) (0)
CLINICAL LOW RISK PROSTATE CANCER: WHAT CAN WE TELL THE PATIENT AT DIAGNOSIS? (2008) (0)
EARLY RECOVERY OF URINARY AND SEXUAL FUNCTION AFTER ROBOTIC-ASSISTED PROSTATECTOMY (2009) (0)
'ATIENTS WITH AN ELEVATED 'E SPECIFIC ANTIGEN LEVEL THERAPEUTIC IRRADIATION FOR POST-PROSTATECTOMY PROSTA (1997) (0)
1895 ASSESSMENT OF EARLY POST-OPERATIVE RECOVERY FOLLOWING RADICAL CYSTECTOMY WITH URINARY DIVERSION USING A VALIDATED INSTRUMENT (2012) (0)
Chapter 35 – Prognostic Significance of Positive Surgical Margins (2003) (0)
Re: Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin. (2013) (0)
Re: Non-O Blood Type is Associated with an Increased Risk of Venous Thromboembolism after Radical Cystectomy (2014) (0)
PREDICTING URINARY FUNCTION AFTER PROSTATE CANCER TREATMENT: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM (2009) (0)
Re: a phase 2 cancer chemoprevention biomarker trial of isoflavone g-2535 (genistein) in presurgical bladder cancer patients. (2013) (0)
OUTCOME ANALYSIS IN PATIENTS WITH A PRE OPERATIVE SERUM PSA OF >or= to 20 Ng./ml. FOLLOWING RADICAL ROSTATECTOMY (1999) (0)
383 ACCEPTANCE OF A PRE-OPERATIVE EDUCATIONAL SEMINAR ABOUT RECOVERY AFTER PROSTATE CANCER SURGERY (2012) (0)
1405 RESULTS FROM A RANDOMIZED CONTROLLED STUDY OF PROSTATE CAPSULE SPARING (PCS) VERSUS NERVE SPARING (NS) CYSTECTOMY AND ORTHOTOPIC NEOBLADDER FOR UROTHELIAL CANCER (2012) (0)
THE QUALITY OF ACTIVE SURVEILLANCE FOR MEN WITH LOW-RISK PROSTATE CANCER (2009) (0)
156 PREDICTORS OF OVERALL, CANCER-SPECIFIC, AND DISEASE-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY IN MEN WITH HIGH-GRADE PROSTATE CANCER (2011) (0)
SHOULD A PATIENT WITH A NORMAL DIGITAL RECTAL EXAMINATION AND AN ABNORMAL TRANS RECTAL ULTRASOUND BE STAGED AS cT1C or cT2 (1999) (0)
IS PELVIC LYMPH NODE DISSECTION NECESSARY AMONG ELDERLY PATIENTS WITH BLADDER CANCER UNDERGOING A RADICAL CYSTECTOMY (2008) (0)
Re: Retrospective Analysis of Survival Outcomes and the Role of Cisplatin-Based Chemotherapy in Patients with Urethral Carcinomas Referred to Medical Oncologists (2014) (0)
Re: Comorbidity and Performance Indices as Predictors of Cancer-Independent Mortality but Not of Cancer-Specific Mortality after Radical Cystectomy for Urothelial Carcinoma of the Bladder (2013) (0)
Re: Pharmacokinetic Study to Optimize the Intravesical Administration of Gemcitabine (2011) (0)
Re: Urinary Cytology for the Detection of Urothelial Carcinoma of the Bladder—A Flawed Adjunct to Cystoscopy? (2014) (0)
Re: Electromotive Instillation of Mitomycin Immediately Before Transurethral Resection for Patients With Primary Urothelial Non-Muscle Invasive Bladder Cancer: A Randomised Controlled Trial (2012) (0)
Re: Contemporary Cost Analysis of Single Instillation of Mitomycin After Transurethral Resection of Bladder Tumor in a Universal Health Care System (2011) (0)
Re: The Retinoblastoma Protein/p16 INK4A Pathway but not p53 is Disrupted by Human Papillomavirus in Penile Squamous Cell Carcinoma (2012) (0)
Re: Instillation of mitomycin C after transurethral resection of bladder cancer impairs wound healing: an animal model. (2012) (0)
2122 CAN TRANSPERINEAL MAPPING TEMPLATE PROSTATE BIOPSY ADEQUATELY PREDICT PROSTATE CANCER LOCALIZATION (2011) (0)
COMPLICATIONS FOLLOWING LAPAROSCOPIC ROBOT-ASSISTED RADICAL PROSTATECTOMY (2010) (0)
Re.: Mechanisms of recurrence of Ta/T1 bladder cancer. (2011) (0)
273: Timing of Recurrence and Outcomes Following Induction BCG for High Risk TA, T1 Bladder Cancer - A Southwest Oncology Group Trial (2004) (0)
Results from the seminal vesicle sparing prostatectomy trial. (2014) (0)
Re: Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression (2012) (0)
310: Early Stage Bladder Cancer Surveillance Does Not Improve Survival if Patients Progress to Clinical T2 Disease (2004) (0)
Re: Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. (2013) (0)
Re: sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. (2013) (0)
Re: Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-directed Intergroup Study (S8710). (2012) (0)
Re: Neoadjuvant Systemic Therapy or Early Cystectomy? Single-Center Analysis of Outcomes After Therapy for Patients With Clinically Localized Micropapillary Urothelial Carcinoma of the Bladder (2012) (0)
Prostate biopsy. (2001) (0)
Re: Comparative Outcomes of Primary, Recurrent, and Progressive High-Risk Non-Muscle-Invasive Bladder Cancer (2014) (0)
Open surgical partial nephrectomy for upper tract urothelial carcinoma (2014) (0)
Re: Long-Term Results of Two Prospective Bladder-Sparing Trimodality Approaches for Invasive Bladder Cancer: Neoadjuvant Chemotherapy and Concurrent Radio-Chemotherapy (2013) (0)
474 ASSOCIATION OF THE NUMBER OF LYMPH NODES (LN) REMOVED AT RADICAL PROSTATECTOMY WITH ALL-CAUSE (ACM) AND PROSTATE CANCER-SPECIFIC MORTALITY (PCSM) (2011) (0)
694 ALLEVIATION VERSUS INDUCTION OF URINARY OBSTRUCTION OR INCONTINENCE BY PROSTATE CANCER TREATMENT THE PIVOTAL ROLE OF PRETREATMENT URINARY SYMPTOMS (2012) (0)
Re: Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. (2015) (0)
1703 A COMPARISON OF PERIOPERATIVE COMPLICATIONS IN BLADDER CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY OR RADICAL CYSTECTOMY, ALONE (2010) (0)
Re: Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. (2012) (0)
CLINICAL TRIAL OF LYCOPENE IN MEN WITH PROSTATE CANCER (2002) (0)
1634 TRANSPERINEAL MAPPING TEMPLATE PROSTATE BIOPSY ADDRESSES UNDER SAMPLING FOR MEN CONSIDERING ACTIVE SURVEILLANCE (2011) (0)
Re: role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies. (2014) (0)
Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderEditorial Comment (2009) (0)
Tomlins Men with Elevated Serum PSA Fusion Transcript Stratifies Prostate Cancer Risk in TMPRSS 2 : ERG Urine (2011) (0)
Re: Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial (2011) (0)
Re: Impact of Patient Age on Outcome Following Bladder-Preserving Treatment for Non-Muscle-Invasive Bladder Cancer (2011) (0)
Re: transurethral resection specimens of the bladder: outcome of invasive urothelial cancer involving muscle bundles indeterminate between muscularis mucosae and muscularis propria. (2011) (0)
Re: Intravesical Delivery of Small Activating RNA Formulated into Lipid Nanoparticles Inhibits Orthotopic Bladder Tumor Growth (2013) (0)
1812 SURGEON VARIANCE IN PATIENT-REPORTED AND CLINICAL OUTCOMES OF RETROPUBIC, LAPAROSCOPIC, OR ROBOTIC RADICAL PROSTATECTOMY (2012) (0)
Re: Continuous Saline Bladder Irrigation After Transurethral Resection is a Prophylactic Treatment Choice for Non-Muscle Invasive Bladder Tumor (2012) (0)
Re: Excision Repair Cross-Complementation Group 1 (ERCC1) Expression in Advanced Urothelial Carcinoma Patients Receiving Cisplatin-Based Chemotherapy (2011) (0)
1133 POST-PROSTATECTOMY SEXUAL AND URINARY FUNCTION AT 3 MONTHS USING THE EXPANDED PROSTATE CANCER INDEX COMPOSITE PREDICTS FUNCTIONAL RECOVERY AT 12 MONTHS (2012) (0)
1376: Why Bladder Cancer Surveillance May not be Effective for High Risk Patients Allowed to Progress to Muscle Invasion (2005) (0)
1345 UNDERSTANDING THE IMPACT OF THE DOMINANT NODULE AND SIZE OF THE PROSTATE ON BIOCHEMICAL RECURRENCE IN MEN WITH PROSTATE CANCER (2013) (0)
Can modifications in surgical technique improve postprostatectomy potency rates in men with prostate cancer? (2005) (0)
Re: growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance. (2011) (0)
Seminar article Clinical interpretation of the prostate biopsy (2003) (0)
Re: Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). (2011) (0)
Re: Squamous Cell Carcinoma of the Penis: Predicting Nodal Metastases by Histologic Grade, Pattern of Invasion and Clinical Examination (2012) (0)
PD15-02 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY (2023) (0)
Re: Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept (2011) (0)
Re: bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. (2012) (0)
Re: Prospective Randomized Trial of Hexylaminolevulinate Photodynamic-Assisted Transurethral Resection of Bladder Tumour (TURBT) plus Single-Shot Intravesical Mitomycin C vs Conventional White-Light TURBT plus Mitomycin C in Newly Presenting Non-Muscle-Invasive Bladder Cancer (2014) (0)
Re: Clinical-Pathologic Stage Discrepancy in Bladder Cancer Patients Treated with Radical Cystectomy: Results from the National Cancer Data Base (2015) (0)
Feasibility and safety of robot-assisted salvage prostatectomy for recurrent prostate cancer following radiation therapy (2008) (0)
515 EXTENT OF LYMPHADENECTOMY AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: A MULTICENTER STUDY (2009) (0)
DISCRIMINATION OF CARE TO PATIENT DIFFERENCES: A USEFUL TOOL FOR EVALUATING QUALITY? (2008) (0)
Re: Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma (2011) (0)
PHENOTYPE OF MICROMETASTATIC CELLS IN THE BONE MARROW OF PATIENTS WITH PROSTATE CANCER (1999) (0)
POD-4.11: Extent of Lymphadenectomy and Biochemical Recurrence After Radical Prostatectomy: A Multicenter Study (2008) (0)
Re: Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, osaka medical college regimen. (2012) (0)
Lack of tumor hypoxia in primary prostate cancer as demonstrated by 18F-FAZA PET/CT and immunohistochemistry (2008) (0)
Letters to the Editor/Errata Re: Location, Extent and Number of Positive Surgical Margins do Not Improve Accuracy of Predicting Prostate Cancer Recurrence After Radical Prostatectomy (2011) (0)
Editorial comment. Biopsy provides useful diagnostic information and should become an integral part of the diagnosis and management of small renal masses. (2009) (0)
PREDICTING ERECTION RECOVERY AFTER PROSTATECTOMY: A MULTIVARIABLE NOMOGRAM FROM THE PROSTQA CONSORTIUM (2009) (0)
Re: Screening Urine Analysis Before Bacille Calmette-Guérin Instillation Does Not Reduce the Rate of Infectious Complications (2013) (0)
Re: discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. (2013) (0)
Editorial comment. (2009) (0)
675: Early Urinary Retention After Catheter Removal Following Radical Prostatectomy is Associated with Future Urethral Stricture Formation (2006) (0)
Re: Variations in Treatment Policies and Outcome for Bladder Cancer in The Netherlands (2011) (0)
454: Effects of Brachytherapy on Racial Treatment Trends in Localized/Regional Prostate Cancer: Contemporary Data from SEER (2004) (0)
Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921. (2017) (0)
Re: Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. (2012) (0)
DEVELOPMENT OF EXPANDED PROSTATE CANCER INDEX COMPOSITE (EPIC) SEXUAL FUNCTION DOMAIN GROUPS TO DEFINE SEVERITY OF SEXUAL DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY (2009) (0)
Re: carcinoma of the urethra: radiation oncology. (2011) (0)
Re: Complications Associated With Primary and Secondary Perforation of the Bladder Following Immediate Instillations of Epirubicin After Transurethral Resection of Superficial Urothelial Tumours (2011) (0)
Re: Long-Term Risk of Progression of Carcinoma In Situ of the Bladder and Impact of Bacille Calmette-Guerin Immunotherapy on the Outcome (2012) (0)
Re: Incidence, Survival and Mortality Rates of Stage-Specific Bladder Cancer in United States: A Trend Analysis (2014) (0)
Re: Predictors of Survival in Patients with Soft Tissue Surgical Margin Involvement at Radical Cystectomy (2014) (0)
Re: A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma. (2011) (0)
PROSPECTIVE MULTICENTER COMPARISON OF OPEN AND ROBOTIC RADICAL PROSTATECTOMY: THE PROST‐QA/RP2 CONSORTIUM: PD18‐08 (2017) (0)
What every urologist should know about a prostate biopsy (2003) (0)
Re: The Role of FISH and Cytology in Upper Urinary Tract Surveillance after Radical Cystectomy for Bladder Cancer (2014) (0)
UTILIZATION OF MEDICATIONS AND DEVICES FOR ERECTILE DYSFUNCTION AFTER PROSTATE CANCER TREATMENT: RESULTS FROM THE MULTICENTER PROSTQA CONSORTIUM (2009) (0)
Re: Evaluation of Different Lymph Node (LN) Variables as Prognostic Markers in Patients Undergoing Radical Cystectomy and Extended LN Dissection to the Level of the Inferior Mesenteric Artery (2012) (0)
Phase II Randomized Clinical Trial of Lycopene Supplementation before Radical Prostatectomy 1 (2001) (0)
Androgen D eprivation a nd F our C ourses o f F ixed-Schedule Suramin T reatment i n P atients W ith N ewly D iagnosed Metastatic P rostate C ancer: A S outhwest O ncology Group S tudy (2000) (0)
Re.: Practice patterns and recurrence after partial cystectomy for bladder cancer. (2011) (0)
Re: Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. (2011) (0)
850 PROSTATE CANCER DETECTION RATES, RISK FACTORS, AND DISTRIBUTION WITH TRANSPERINEAL MAPPING TEMPLATE PROSTATE BIOPSY: INITIAL SINGLE INSTITUTION EXPERIENCE (2011) (0)
Re: Two Major Pathways of Penile Carcinogenesis: HPV-Induced Penile Cancers Overexpress p16ink4a, HPV-Negative Cancers Associated with Dermatoses Express p53, but Lack p16ink4a Overexpression (2014) (0)
When does lymphadenectomy improve survival of patients with genitourinary malignancies? (2009) (0)
Re: Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. (2013) (0)
Re: the role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. (2012) (0)
Re: Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer (2014) (0)
168 INCIDENCE AND IMPACT ON 15 YEAR SURVIVAL (DOC V DOD) OF GLEASON UPGRADING AFTER RADICAL PROSTATECTOMY (2012) (0)
1645 SHOULD PERINEURAL INVASION IN RADICAL PROSTATECTOMY SPECIMENS INFLUENCE SURVEILLANCE AMONG PROSTATE CANCER SURVIVORS? LONGITUDINAL EXPERIENCE IN 3,226 PATIENTS (2011) (0)
FIVE YEAR CHANGE IN URINARY INCONTINENCE AND IRRITATIVE SYMPTOMS AFTER PROSTATE CANCER TREATMENT MEASURED WITH A VALIDATED QUALITY OF LIFE QUESTIONNAIRE (2009) (0)
Vascular endothelial growth factor-C associated with computed tomography used in the diagnosis of lymph node metastasis of bladder carcinoma. (2011) (0)
Adult UrologySexual Function/InfertilityEditorial Comment (2008) (0)
Re: Pathological Stage Review is Indicated in Primary pT1 Bladder Cancer. (2011) (0)
Re: readaptation of the peritoneum following extended pelvic lymphadenectomy and cystectomy has a significant beneficial impact on early postoperative recovery and complications: results of a prospective randomized trial. (2012) (0)
Re: extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. (2013) (0)
Re: Intravesical Bacille Calmette-Guérin (BCG) in Immunologically Compromised Patients with Bladder Cancer (2014) (0)
Re: Large Cell Undifferentiated Carcinoma of the Urinary Bladder (2011) (0)
Re: Gene Signatures for the Prediction of Response to Bacillus Calmette-Guerin Immunotherapy in Primary pT1 Bladder Cancers. (2011) (0)
EXPERIMENTAL LAPAROSCOPIC PARTIAL NEPHRECTOMY: HYDRO-JET DISSECTION IN A PORCINE MODEL - INITIAL EXPERIENCE (1999) (0)
Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the B (2011) (0)
Re: Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and is Minimally Affected by Radical Cystectomy (2011) (0)
The evolving role of surgery in the management of renal cell carcinoma. (1989) (0)
Re: Robotic-Assisted Radical Cystectomy with Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients with a Median Follow-up of 3 Years (2014) (0)
COMPARING EPIC TO ISI AND SHIM IN MEASURING FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY: THE ARGUMENT FOR A SINGLE BROAD-DOMAIN ASSESSMENT TOOL (2009) (0)
Neoadjuvant docetaxel and capecitabine in patients (Pts) with high-risk prostate cancer (PCa): Final results of a phase II trial (2007) (0)
Re: Analysis of Radical Cystectomy and Urinary Diversion Complications with the Clavien Classification System in an Italian Real Life Cohort (2014) (0)
1166: Urologic Oncology Training May Improve Early Experience with Robot-Assisted Radical Prostatectomy (2006) (0)
Re: A 1-Year Maintenance After Early Adjuvant Intravesical Chemotherapy has a Limited Efficacy in Preventing Recurrence of Intermediate Risk Non-Muscle-Invasive Bladder Cancer (2011) (0)
Adult urologyOncology: Prostate/testis/penis/urethraEditorial Comment (2007) (0)
Re: Induction Chemotherapy for Unresectable Urothelial Carcinoma of the Bladder (2011) (0)
Re: increased incidence of penile cancer and high-grade penile intraepithelial neoplasia in denmark 1978-2008: a nationwide population-based study. (2013) (0)
Performance of multi-modality molecular imaging of prostate cancer (2008) (0)
Epidemiology of Renal Tumors (2008) (0)
Re: Inhibition of Bladder Cancer by Broccoli Isothiocyanates Sulforaphane and Erucin: Characterization, Metabolism, and Interconversion (2013) (0)
554: Prospective Comparison of Short-Term Recovery between Open and Robotic Radical Prostatectomy (2007) (0)
MP51-10 PREDICTORS OF FAVORABLE URINARY OUTCOMES AFTER PROSTATE CANCER TREATMENT (2014) (0)
Re: Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. (2012) (0)
Re: urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. (2012) (0)
Should patients with high-risk prostate cancer receive 6 months or 3 years of adjuvant androgen suppression therapy? (2007) (0)
Re: Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? (2012) (0)
Distal hypospadias in the adult. (1990) (0)
Prostate cancer old problems and new approaches (1996) (0)
2215 TRANSPERINEAL MAPPING TEMPLATE PROSTATE BIOPSY AFTER PREVIOUS TRANSRECTAL ULTRASOUND PROSTATE BIOPSY DETECTS WORSE DISEASE BURDEN (2013) (0)
Management and Controversies of High-Grade Prostatic Intraepithelial Neoplasia and Atypical Small Acinar Proliferation on Prostate Biopsy (2008) (0)
Re: Quality of care in patients with bladder cancer: a case report? (2013) (0)
992 15-YEAR ALL-CAUSE MORTALITY (ACM) AND PROSTATE CANCER-SPECIFIC MORTALITY (PCSM) AMONG MEN WITH BIOPSY GLEASON 2-6 CANCERS (2012) (0)
COMPARISON OF BODY IMAGE BETWEEN ILEAL CONDUIT AND ORTHOTOPIC NEOBLADDER PATIENTS AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER (2009) (0)
Re: intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. (2013) (0)
Re: phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David P. Jr. Wood?

David P. Jr. Wood is affiliated with the following schools:

University of Kentucky
University of Michigan
Wayne State University